DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

MRI Homepage

MR shows promise for predicting neurological outcomes in cardiac arrest survivors May also help develop therapies

New research finds brain MR study groups don't reflect U.S. population demographics This must change for large, multicenter studies

Bracco Imaging acquires SurgVision Enables development of a real-time fluorescence image-guided surgery platform

What’s new in MR scanners and coils? A review of new innovations arriving on market

Purchasing Insights: The ABCs of buying an MR Facilities must think about their scanning needs of tomorrow when investing today

Siemens gets 7T MR cleared for clinical use in U.S. MAGNETOM Terra offers benefits for neuro and MSK imaging

MR detects neurological impairments in newborns with CHD before surgery Detects brain impairments even before cardiac surgery

Anthem presses forward with new MR, CT reimbursement guidelines An effort to increase usage of free-standing scan facilities

Merry X-Ray acquires Consensys Imaging Service Expands presence in MR, CT and other imaging modality markets

The future of AI in MR: Supporting clinical decisions Insights from Murat Gungor, vice president of Magnetic Resonance (MR) at Siemens Healthineers North America

Doctors consider and discuss options
regarding an MR image of the brain

Contrasting viewpoints on gadolinium

by Gus Iversen , Editor in Chief
From the October 2017 issue of DOTmed HealthCare Business News magazine

Gadolinium contrast agents are used in 40 to 50 percent of MR scans and, by some estimates, roughly 400 million doses have been administered since it was introduced in 1988.

For most of those years, the agent appeared to have virtually no drawbacks, but over the last decade or so, the medical imaging community has been forced to reexamine that narrative.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



In 2006, researchers discovered that the agent put patients with renal insufficiencies at risk of nephrogenic systemic fibrosis. Then, in 2013, findings surfaced suggesting that gadolinium could accumulate in the brain of patients undergoing multiple scans.

Since then, the question that remains unanswered has been: what are the clinical implications for gadolinium accumulation in the brain?

Assessing risks
In March, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) concluded an assessment of gadolinium agents and recommended regulatory actions, including suspension for some marketing authorizations.

Two months later, the FDA weighed in on gadolinium with its own findings. The agency announced that, after a two-year study of the issue, it had not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for MR imaging.

“Our recommendations for health care professionals and patients remain unchanged from July 2015, when we informed the public that we were investigating this potential risk with GBCAs,” the agency wrote in a statement. “Because we identified no evidence to date that gadolinium retention in the brain from any of the GBCAs, including GBCAs associated with higher retention of gadolinium, is harmful, restricting GBCA use is not warranted at this time.”

Despite those findings, an FDA panel voted in September to add retention warnings to the labeling of gadolinium agents. The group also voted unanimously (15-0) in favor of requiring contrast manufacturers to conduct more studies aimed at understanding the implications of gadolinium retention and any health risks that may accompany it.

Macrocyclic versus linear gadolinium contrast agents
Gadolinium retention rates appear to be lower with macrocyclic agents – such as Dotarem (Guerbet), Gadavist (Bayer) and ProHance (Bracco) – than with linear agents. For that reason, the PRAC recommendations refer to linear agents – such as MultiHance (Bracco), Omniscan (GE Healthcare), Magnevist (Bayer) and Optimark (Guerbet).

Still, in some cases, the PRAC recommended keeping particular linear agents available. For example, it determined that gadoxetic acid (a linear agent marketed by Bayer as Primovist in Europe and Eovist in the U.S.) should remain on the market because it meets an important diagnostic need in patients with few alternatives.
  Pages: 1 - 2 - 3 >>

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED